Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Monopar Therapeutics Inc (MNPR)
NASDAQ:MNPR
RESEARCH TOOLSreports
Monopar Therapeutics Inc (MNPR) Stock Price & Analysis
333 Followers
MNPR Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.27 - $1.73
Previous Close$0.68
Volume48.39K
Average Volume (3M)110.33K
Market Cap
$11.86M
Enterprise Value$6.34M
Total Cash (Recent Filing)$5.52M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 08, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding17,484,175
10 Day Avg. Volume201,945
30 Day Avg. Volume110,327
Standard Deviation0.29
R-Squared0.05
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)1.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.65
Forecast
1Y Price Target
$2.00Price Target Upside196.30% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Monopar Therapeutics Inc News
PremiumCompany Announcements
Monopar Therapeutics Begins Pioneering MNPR-101-Zr Trial
PremiumCompany Announcements
Monopar Therapeutics Enhances Alliance with NorthStar Medical
PremiumCompany Announcements
Monopar Therapeutics Showcases MNPR-101-Zr Progress at SNMMIBulls Say, Bears Say
Bulls Say
Clinical TrialsMonopar announced initiation of the Phase 1 dosimetry trial in Australia.
Financial StabilityManagement announced cash runway at least through June 30, 2025.
Preclinical ResultsThe preclinical results demonstrate the tumor-targeting ability of MNPR-101 and near complete elimination of tumors in xenograft mouse models after a single injection.
Bears Say
Capital RaiseFailure to secure a capital raise may hinder the company's financial stability.
Clinical TrialsClinical trial failure poses a significant risk to the stock.
Safety ConcernsSafety concerns with camsirubicin at high dose levels could negatively impact investor confidence.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MNPR FAQ
What was Monopar Therapeutics Inc’s price range in the past 12 months?
Monopar Therapeutics Inc lowest stock price was $0.27 and its highest was $1.73 in the past 12 months.
What is Monopar Therapeutics Inc’s market cap?
Currently, no data Available
When is Monopar Therapeutics Inc’s upcoming earnings report date?
Monopar Therapeutics Inc’s upcoming earnings report date is Aug 08, 2024 which is in 17 days.
How were Monopar Therapeutics Inc’s earnings last quarter?
Monopar Therapeutics Inc released its earnings results on May 09, 2024. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.145 by $0.045.
Is Monopar Therapeutics Inc overvalued?
According to Wall Street analysts Monopar Therapeutics Inc’s price is currently Undervalued.
Does Monopar Therapeutics Inc pay dividends?
Monopar Therapeutics Inc does not currently pay dividends.
What is Monopar Therapeutics Inc’s EPS estimate?
Monopar Therapeutics Inc’s EPS estimate is -$0.09.
How many shares outstanding does Monopar Therapeutics Inc have?
Monopar Therapeutics Inc has 17,568,174 shares outstanding.
What happened to Monopar Therapeutics Inc’s price movement after its last earnings report?
Monopar Therapeutics Inc reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.145. Following the earnings report the stock price went down -5.333%.
Which hedge fund is a major shareholder of Monopar Therapeutics Inc?
Currently, no hedge funds are holding shares in MNPR
---
Monopar Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (196.30% Upside)
$2.00 (196.30% Upside)
Insider Transactions
Bought Shares
Worth $99.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.7%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.08%
12-Months-Change
Fundamentals
Return on Equity
-92.67%
Trailing 12-Months
Asset Growth
-24.68%
Trailing 12-Months
Company Description
Monopar Therapeutics Inc
Monopar Therapeutics, Inc. engages in developing orphan oncology drugs. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.
---
MNPR Stock 12 Month Forecast
Average Price Target
$2.00
▲(196.30% Upside)
Technical Analysis
Best Analysts Covering MNPR
1 Year
1 Year Success Rate
1/22 ratings generated profit
1 Year Average Return
-43.56%
upgraded a buy rating 3 months ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 4.55% of your transactions generating a profit, with an average return of -43.56% per trade.
---